Uncertainty around President Donald Trump’s tariff policies have sent the major averages on a roller-coaster ride and spurred ...

"I think the geopolitical stuff is paramount for the free world, far more important ... deal was a blow to rival obesity drugmaker Novo Nordisk. Its stock fell nearly 4%, while Eli Lilly's ...

and Novo Nordisk. On 14 November, Eli Lilly became a part of this group, after an account using its name and logo sent out a Tweet, which read: “We are excited to announce insulin is free now.” ...

“But it’s more than a response to the full-scale invasion in Ukraine: with EDIP [the European Defence Industry Program, a cash pot worth €1.5 billion], but also the European Defence Fund, the upcoming ...

Novo Nordisk shares rose Monday as the company said it would present new data on the ability of semaglutide, the active ...

Danish company Novo Nordisk's membership in a UK pharmaceutical industry body has been restored after a two-year suspension ...

In a report released today, Jo Walton from UBS maintained a Buy rating on Novo Nordisk (0QIU – Research Report), with a price target of ...

Goldman Sachs analyst James Quigley maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of DKK890.00. The company’s shares closed yesterday at DKK597.63.

Shares of Novo Nordisk slipped in Monday morning trading after the company announced results of its latest weight-loss drug trial. Novo's results from its Redefine 2 late-stage trial of ...

Novo Nordisk announced that its next-generation weight-loss drug CagriSema helped obese or overweight adult patients with type 2 diabetes lose 15.7% of their weight in a recent trial. That figure ...

Shares of Novo Nordisk fell on Monday, after the Danish pharmaceutical giant said its next-generation weight-loss drug CagriSema helped obese or overweight adult patients with type 2 diabetes drop ...